





In the last 5 years I have received research
grants, honoraria and consultancy from
manufacturers of antihypertensive, 
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5Global burden of blood-pressure-related 
disease, 2001
Worlwide, 7.6 million premature deaths (about
13.5% of the global total) were attributed to high
BP (> 115 mmHg). About 54% of stroke and 
47% of IHD were attributable to BP.
About half of this burden was in people
with prehypertension
Lawes CMM et al, Lancet 2008; 371:1513-1518
Egan B & Stevens‐Fabry S. Prehypertension‐prevalence, health
risks and management strategies. Nat Rev Cardiol 2015; 12:289‐
300
‐ 25‐50 % of adults worlwide and increases the risk of
incident hypertension
‐ The risk of incident hypertension decreases by 34‐66%
single antihypertensive therapy
‐ The RR of incident CVD is greater in “high‐normal” BP 
and CV mortality is increased
‐ 10‐year absolute risk for middle‐aged adults without
diabetes or CVD is around 10%. It rises to around 40%
with either or both comorbidities
‐ Antihypertensive therapy reduces the RR od CVD and 




BP Thresholds for and Goals of Pharmacological Therapy in 









Clinical CVD or 10-year ASCVD risk ≥10% ≥130/80 <130/80
No clinical CVD and 10-year ASCVD risk <10% ≥140/90 <130/80
Older persons (≥65 years of age; noninstitutionalized, 
ambulatory, community-living adults)
≥130 (SBP) <130 (SBP)
Specific comorbidities
Diabetes mellitus ≥130/80 <130/80
Chronic kidney disease ≥130/80 <130/80
Chronic kidney disease after renal transplantation ≥130/80 <130/80
Heart failure ≥130/80 <130/80
Stable ischemic heart disease ≥130/80 <130/80
Secondary stroke prevention ≥140/90 <130/80
Secondary stroke prevention (lacunar) ≥130/80 <130/80
Peripheral arterial disease ≥130/80 <130/80
ASCVD indicates atherosclerotic cardiovascular 
disease; BP, blood pressure; CVD, cardiovascular 






Category Systolic (mmHg) Diastolic (mmHg)
Optimal < 120 and < 80
Normal 120–129 and/or 80‐84
High normal 130–139 and/or 85‐89
Grade 1 hypertension 140–159 and/or 90‐99
Grade 2 hypertension 160–179 and/or 100‐109
Grade 3 hypertension ≥ 180 and/or ≥ 110



































































































































































Consider beta‐blockers at any treatment step, when there is a 














Non-adherence to antihypertensive medicines in the 
real world – according to number of medicines
Gupta P, Tomazewski M, Williams B, et al. Hypertension 2017
UK
Czech Republic
Patients prefer to take 1 pill
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• In treated hypertensives daytime WUCH appears in 29% of the
patients ND MUCH IN 32% (INADEQUATE EVALUATION IN 61% OF 
PATIENTS). In diabetic patients 33% and 24%.
• Office BP measured only twice
• Automated office BP measurement contributes to diminish the
prevalence of WCH and WUCH (3 measures with OMROM as in 
SPRINT or 5 times with BP‐TRUE)
• HBPM can also help to detect all the phenotypes of BP
SABPRE (Spanish Ambulatory BP Registry)
Banegas JR, Ruilope LM et al, Hypertension 2016
Screening and diagnosis of hypertension
Association of hypertension phenotypes with CV mortality  
in fully-adjusted Cox Models de Regresión de Cox (model 2).
Based on: 
Banegas JR et al. N Engl J Med 2018;378:1509‐1520.































3‐ Hazard ratio for mortality higher in patients with MUCH and 
office BP < 130/80 mmHg (2.89 vs 2.42)
Ruilope et al, Hypertension 2019

















































7.5 mg 10 mg 15 mg 20 mgPlacebo
Systolic 
Diastolic 
Error bars represent standard deviation Adapted from Bakris G et.al. JAMA. 2015;314(9):884‐894
N= 645
Follow‐up 1 year
Screening Blood Pressure –
Office Blood Pressure vs. ABPM 
(never-treated hypertensives NTH) 
J Am Soc Hypertens. 2016 Jul;10 Suppl 1:e7.
Screening Blood Pressure –
Office Blood Pressure vs. ABPM (MUCH)
J Am Soc Hypertens. 2016 Jul;10 Suppl 1:e7.
ABPM Nocturnal Hypertension (yes)–
Change in Systolic Blood Pressure per visit
www.escardio.org/guidelines
TREATMENT OF RISK PHENOTYPES
OBSERVED IN ABPM IN CKD
1‐WCH START WITH MONOTHERAPY?
2‐MH START WITH LOW DOSE COMBINATION
3‐ WUCH ADD A NEW DRUG 
4‐ MUCH ADD A NEW DRUG
AFTER INITIAL THERAPY FOLLOW GUIDELINES
